Lab21 is a leading provider of cutting edge diagnostics, supporting drug discovery, healthcare and environmental monitoring. Its customers include healthcare providers, pharmaceutical and biotechnology companies in addition. The Company supports organisations that need to monitor their impact on the environment.
Lab21 has a rapidly growing portfolio of diagnostics to support early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry. A key function is the support of clinicians and healthcare providers as they treat and monitor patients.
The company's products include diagnostic tests for cancer, liver disease, respiratory illnesses and infectious diseases such as syphilis through its subsidiary Newmarket Laboratories. Its pharmaceutical support services which focus on anti-viral programmes include lead identification and optimisation of targets, drug resistance profiling, mode of action studies, and drug combination studies as well as clinical trial support.
The Lab21 group includes MTI (Monitoring Technologies International), a company specialising in the development of environmental monitoring instruments, and Newmarket Laboratories, which specialises in the development and production of high-quality immunodiagnostics for infectious diseases.
